PSNL vs. VRDN, CDNA, AHCO, PNTG, AVAH, CSTL, AUNA, FLGT, TALK, and SBC
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Viridian Therapeutics (VRDN), CareDx (CDNA), AdaptHealth (AHCO), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Castle Biosciences (CSTL), Auna (AUNA), Fulgent Genetics (FLGT), Talkspace (TALK), and SBC Medical Group (SBC). These companies are all part of the "healthcare" industry.
Personalis vs.
Viridian Therapeutics (NASDAQ:VRDN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
Personalis has a net margin of -104.52% compared to Viridian Therapeutics' net margin of -85,127.16%. Personalis' return on equity of -66.07% beat Viridian Therapeutics' return on equity.
Viridian Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
61.9% of Personalis shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by insiders. Comparatively, 4.1% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Personalis received 49 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.72% of users gave Viridian Therapeutics an outperform vote while only 67.96% of users gave Personalis an outperform vote.
Personalis has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Personalis had 7 more articles in the media than Viridian Therapeutics. MarketBeat recorded 20 mentions for Personalis and 13 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.46 beat Personalis' score of 0.11 indicating that Viridian Therapeutics is being referred to more favorably in the media.
Viridian Therapeutics presently has a consensus target price of $35.70, indicating a potential upside of 147.74%. Personalis has a consensus target price of $7.75, indicating a potential upside of 88.56%. Given Viridian Therapeutics' higher probable upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Personalis.
Summary
Personalis beats Viridian Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
This page (NASDAQ:PSNL) was last updated on 3/4/2025 by MarketBeat.com Staff
